Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
HELP
HELP
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
HELP News
Helus Pharma Advances New Drug for Anxiety Treatment
22h ago
Newsfilter
Helus Pharma Advances Mental Health Treatments with Promising Phase 2 Results
23h ago
PRnewswire
Helus Pharma's Anxiety Drug Trial Results Trigger Stock Plunge
4d ago
stocktwits
US Stock Futures Stabilize Amid Oil Price Surge
4d ago
stocktwits
Helus Pharma's HLP004 Phase 2 Study Results Disappoint
4d ago
Benzinga
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
4d ago
PRnewswire
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
4d ago
Newsfilter
Helus Pharma Reports Significant Phase 2 Trial Results for Anxiety Disorder Therapy
5d ago
seekingalpha
Helus Pharma Reports Promising Early Results for HLP004 Anxiety Treatment
5d ago
stocktwits
Helus Pharma Announces Phase 2 Results for HLP004 in GAD Treatment
5d ago
Newsfilter
Helus Pharma Advances Mental Health Drug Development
Feb 27 2026
Newsfilter
Helus Pharma Advances Psychedelic Drug Clinical Trials
Feb 27 2026
PRnewswire
Helus Pharma's Psychedelic Drug Achieves Phase 3 Success
Feb 26 2026
PRnewswire
Helus Pharma Achieves Breakthrough in Depression Treatment
Feb 26 2026
Newsfilter
Mental Health Treatment Market Set for Accelerated Growth
Feb 24 2026
PRnewswire
Mental Health Drug Market Set for Accelerated Growth
Feb 24 2026
Newsfilter
Show More News
